Prospective Clinical Study of Orelabrutinib in Combination With Rituximab (OR) for Primary Marginal Zone Lymphoma (MZL) That Failed or Not Suitable for Local Therapy

NCT06478472 · clinicaltrials.gov ↗
NA
Phase
RECRUITING
Status
36
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

The First Affiliated Hospital of Xiamen University

Collaborators